TransCode Therapeutics, Inc., an RNA oncology company, has announced on November 5, 2024, that it has been granted an extension by the Nasdaq Hearings Panel to continue its listing on The Nasdaq Stock Market. This decision, which follows the company's appearance before the panel on October 1, 2024, comes with specific conditions that TransCode must meet to regain compliance with Nasdaq's listing standards. The issues of non-compliance included the bid price, equity, and shareholder approval requirements as per Nasdaq's Listing Rules. Alongside this announcement, TransCode received a Public Reprimand Letter. The company, which is in the clinical stage and focuses on metastatic disease treatment through RNA therapeutics, is developing its lead therapeutic candidate, TTX-MC138, targeting metastatic tumors. TransCode's proprietary TTX nanoparticle platform is central to its strategy for designing and delivering RNA therapeutics. The company also highlighted the risks associated with its business, including drug development, clinical trial outcomes, financial condition, regulatory submissions, intellectual property, competition, dependencies on third parties, and external events such as pandemics and geopolitical actions.

TransCode Therapeutics, Inc., an RNA oncology company, has announced on November 5, 2024, that it has been granted an extension by the Nasdaq Hearings Panel to continue its listing on The Nasdaq Stock Market. This decision, which follows the company's appearance before the panel on October 1, 2024, comes with specific conditions that TransCode must meet to regain compliance with Nasdaq's listing standards. The issues of non-compliance included the bid price, equity, and shareholder approval requirements as per Nasdaq's Listing Rules. Alongside this announcement, TransCode received a Public Reprimand Letter. The company, which is in the clinical stage and focuses on metastatic disease treatment through RNA therapeutics, is developing its lead therapeutic candidate, TTX-MC138, targeting metastatic tumors. TransCode's proprietary TTX nanoparticle platform is central to its strategy for designing and delivering RNA therapeutics. The company also highlighted the risks associated with its business, including drug development, clinical trial outcomes, financial condition, regulatory submissions, intellectual property, competition, dependencies on third parties, and external events such as pandemics and geopolitical actions.